• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

    5/9/25 9:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    • Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis
    • Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination
    • Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness

    GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m. CT, Pretty Hurts features a storyline that aims to raise awareness among parents about meningococcal disease, known as meningitis, an uncommon but serious illness that teens and young adults aged 16-23 are at an increased risk for.1,2,3 GSK provided financial and content support for the film, which alerts moms that while many teens have received vaccination against meningitis serogroups A, C, W, and Y, many may be missing meningitis B vaccination.4

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507580900/en/

    The film follows Julie, played by actress Haylie Duff, a relatable mom juggling the demands of family life and a career, while navigating the challenges of parenting a teen in high school. After Julie's daughter, Lauren, enters a beauty pageant to win scholarship money for college, meningitis suddenly strikes close to home, showcasing the impact of the disease on both their family and an entire community.

    As the newest spokesperson for the larger Ask2BSure campaign, Alyson Hannigan, seasoned actress and mom to a 16-year-old, knows parenting teens is a job with no script. Hannigan was moved to join Ask2BSure after hearing the real stories of families impacted by meningitis. GSK honors the experiences of those families with this Lifetime movie.

    Hannigan said: "As a mom, I know how hard it can be to stay on top of everything, especially when it comes to my teen's health, and it is so important to ask the right questions about meningitis risk and vaccination. I'm proud to have joined the Ask2BSure campaign so that I can empower other parents to speak up and ask their teen's doctor for more information."4

    Pretty Hurts builds off the 2023 GSK and Lifetime co-branded short film, "I Never Thought to Ask: A Mom's Quest for Answers," which also brought awareness to meningitis B and vaccination.

    Cynthia Burman, US Medical Affairs Lead for Neisseria Vaccines for GSK, said: "Working with Lifetime on this longer-form creative and educational film allows us to deliver impactful content to help empower parents in the US to start the conversation with their teen's doctor to find out if their teen is missing any meningococcal vaccinations."4,5

    Pretty Hurts is intended for viewers in the US. The movie premieres on Lifetime on June 28 at 8 p.m. ET and will be available for viewing starting June 29 on MyLifetime.com/movies.

    About GSK's Ask2BSure Campaign

    Ask2BSure aims to educate and empower parents of teens and young adults to start meningitis conversations with their teen's doctors and "ask to be sure" their teen has received vaccination to help protect against all five vaccine-preventable serogroups of meningitis. Vaccination may not protect all recipients. Find out more at Ask2BSure.com.

    About GSK

    GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

    Cautionary statement regarding forward-looking statements

    GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2024.

    Registered in England & Wales:

    No. 3888792

    Registered Office:

    980 Great West Road

    Brentford, Middlesex

    TW8 9GS

    References:

    1. Centers for Disease Control and Prevention. Risk Factors for Meningococcal Disease. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/risk-factors/index.html#cdc_risk_factors_who-people-at-increased-risk. Accessed May 2025.

    2. Centers for Disease Control and Prevention. Meningococcal Disease Surveillance and Trends. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/php/surveillance/index.html. Accessed May 2025.

    3. Centers for Disease Control and Prevention. Clinical Overview of Meningococcal Disease. Available at https://www.cdc.gov/meningococcal/hcp/clinical/index.html. Accessed May 2025.

    4. Pingali C, Yankey D, Chen M, et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2023. MMWR Morb Mortal Wkly Rep 2024; 73:708–714. Available at: https://www.cdc.gov/mmwr/volumes/73/wr/mm7333a1.htm. Accessed May 2025.

    5. Centers for Disease Control and Prevention. Meningococcal Vaccination for Adolescents: Information for Healthcare Professionals. Available at: https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/?CDC_AAref_Val=https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Accessed May 2025.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507580900/en/

    GSK inquiries



    Media:

    Kathleen Quinn, +1 202 603 5003, (Washington DC)

    Alison Hunt, +1 540 742 3391, (Washington DC)



    Investor Relations:

    Frannie DeFranco, +1 215 751 4855, (Philadelphia)

    Jeff McLaughlin, +1 215 751 7002, (Philadelphia)

    Get the next $GSK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GSK

    DatePrice TargetRatingAnalyst
    6/3/2025Buy → Hold
    Berenberg
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    2/12/2025Equal-Weight
    Morgan Stanley
    11/15/2024Buy → Hold
    Deutsche Bank
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    10/31/2024Buy → Neutral
    Guggenheim
    7/8/2024Buy → Neutral
    UBS
    5/30/2024$47.00Neutral
    Goldman
    More analyst ratings

    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GlaxoSmithKline downgraded by Berenberg

      Berenberg downgraded GlaxoSmithKline from Buy to Hold

      6/3/25 7:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

      With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis (LN) who are receiving standard therapy. With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option

      6/24/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

      Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 GSK plc (LSE/NYSE:GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays

      6/16/25 9:33:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

      Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces

      6/2/25 6:00:00 AM ET
      $GSK
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      6/27/25 6:35:35 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      6/26/25 7:14:52 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      6/25/25 6:10:09 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 700,772 units of Common Stock and bought $4,950,000 worth of Common Stock (275,000 units at $18.00)

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:38:14 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by GLAXOSMITHKLINE PLC

      3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:22:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 30,253,189 units of Common Stock

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      6/23/21 6:14:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care